- Home
- MRK
as 12-20-2024 4:00pm EST
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | KENILWORTH |
| Market Cap: | 260.8B | IPO Year: | N/A |
| Target Price: | $129.07 | AVG Volume (30 days): | 14.0M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.78 | EPS Growth: | 165.47 |
| 52 Week Low/High: | $94.48 - $134.63 | Next Earning Date: | 02-04-2025 |
| Revenue: | $63,174,000,000 | Revenue Growth: | 6.51% |
| Revenue Growth (this year): | 7.49% | Revenue Growth (next year): | 4.97% |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
TipRanks
17 hours ago
Personalis price target raised to $8 from $7 at BTIG
TipRanks
17 hours ago
Merck closes exclusive global license agreement for LM-299 from LaNova Medicines
Investing.com
2 days ago
BMO cuts rating on Merck and Biogen, on lack of near term catalyst
Simply Wall St.
2 days ago
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain
Zacks
2 days ago
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Insider Monkey
2 days ago
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?
Business Wire
2 days ago
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
MT Newswires
2 days ago
BMO Capital Downgrades Merck & Co. to Market Perform From Outperform, Adjusts Price Target to $105 From $136
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.